(Q41521276)

English

Troglitazone

scientific article published on July 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 October 2017

1 reference

Europe PubMed Central

Troglitazone (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 October 2017

author name string

Spencer CM

1

1 reference

Europe PubMed Central

PubMed publication ID

2 October 2017

Markham A

2

1 reference

Europe PubMed Central

PubMed publication ID

2 October 2017

publication date

1 July 1997

1 reference

Europe PubMed Central

PubMed publication ID

2 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 October 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

2 October 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

2 October 2017

89-101; discussion 102

1 reference

Europe PubMed Central

PubMed publication ID

2 October 2017

https://scigraph.springernature.com/pub.10.2165/00003495-199754010-00010

0 references

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro studies on the action of CS-045, a new antidiabetic agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CS-045, a new oral antidiabetic agent, stimulates fructose-2,6-bisphosphate production in rat hepatocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9211083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199754010-00010

1 reference

Europe PubMed Central

PubMed publication ID

2 October 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41521276&oldid=1923654581"